David Goldstein, Actio Biosciences CEO
June 18, 2025 07:00 AM EDT
Financing

Ac­tio gets $66M for ex­per­i­men­tal epilep­sy and Char­cot-Marie-Tooth treat­ments

Kyle LaHucik

Biotech Correspondent

An im­pres­sive group of bio­phar­ma in­vestors put $66 mil­lion in­to a San Diego start­up called Ac­tio Bio­sciences.

The clin­i­cal-stage com­pa­ny said Wednes­day morn­ing that ex­ist­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

Schol­ar Rock’s mus­cle-pre­serv­ing obe­si­ty drug add-on looks com­pet­i­tive

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

CBER head Prasad adds chief med­ical and sci­en­tif­ic of­fi­cer to his ti­tle

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times